longevity-biotech
(2)
Zoe Biosciences Found a Longevity Clue in Amish DNA. Now It Has to Turn That Clue Into a Drug
A rare mutation pointed to longer, healthier lives. Zoe's bet is that two drug programs can borrow the biology without borrowing the mutation - and its newest mouse data put obesity, muscle preservation and a very expensive clinical test on the same page.
Adam Freund
Adam Freund is the founder and CEO of Arda Therapeutics, a San Carlos biotech built on a simple, contrarian bet: many chronic diseases are caused by specific cells gone wrong, so the cure is to find and delete those cells while leaving healthy tissue intact. A molecular biologist with a Berkeley PhD and a Stanford postdoc, he spent seven years at Google-backed Calico Life Sciences, where he helped grow the company from roughly 15 to 200-plus people and started its most advanced anti-aging therapeutic program. In late 2021 he left to start Arda as a solo founder with a deck and a thesis, and by October 2024 had raised a $43M Series A led by a16z Bio + Health. His tools are single-cell sequencing to map disease cell-by-cell and antibodies to do the deleting.